Previous 10 | Next 10 |
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division - Enzo Life Sciences reports revenue of $7.5 million, with Jan-23 revenue of $3.6M as the second highest monthly revenue in over 10 years FARMINGDALE, N...
2023-03-20 06:00:00 ET 3 Sectors to Find Penny Stocks That Could Be Worth Buying Navigating the vast landscape of penny stocks can be an exciting venture for investors looking to capitalize on hidden gems. Although these stocks are often seen as risky due to their low price, they can of...
2023-03-18 06:00:00 ET 3 Tips for Making Money With Penny Stocks in 2023 As an investor looking to succeed with penny stocks , it’s essential to develop a winning mindset that will enable you to make the most out of small-cap investments in 2023. One of the keys to success in...
2023-03-17 10:02:41 ET Gainers: Enzo Biochem ( ENZ ) +77% . PaxMedica ( PXMD ) +22% . Nuwellis (NUWE ) +18% . Lucy Scientific Discovery ( LSDI ) +12% . Assure Holdings ( IONM ) +8% . Losers: Lifecore Biomedical (...
2023-03-17 08:22:48 ET Enzo Biochem ( NYSE: ENZ ) +73% . PaxMedica ( PXMD ) +27% . FedEx ( FDX ) +11% . BigBear.ai Holdings ( BBAI ) +11% . Riot Blockchain ( RIOT ) +11% . Corbus Pharmaceuticals Holdings ( CRBP ) +10% ...
2023-03-16 17:07:30 ET Enzo Biochem ( NYSE: ENZ ) on Thursday said it has sold its Clinical Laboratory division to Labcorp ( NYSE: LH ). Financial details of the transaction were not disclosed. “Completion of the sale will position Enzo to assess and exe...
Significant value unlocked for Enzo shareholders with continued focus on remaining businesses. FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’...
Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Conference Call December 13, 2022 08:30 A.M. ET Company Participants Unidentified Company Representative - IR Hamid Erfanian - CEO Patricia Eckert - Interim CFO Conference Call Participants Presentation Op...
Enzo Biochem press release ( NYSE: ENZ ): Q1 Non-GAAP EPS of -$0.18. Revenue of $18.28M (-31.1% Y/Y). For further details see: Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX - Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well. - Continuing to make progress ...
News, Short Squeeze, Breakout and More Instantly...
Enzo Biochem Inc. Company Name:
ENZ Stock Symbol:
NYSE Market:
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's...
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fis...